NCT05143905 is a Phase 1 clinical trial of AZD7503 in Safety, sponsored by AstraZeneca.

Who is sponsoring NCT05143905?

NCT05143905 is sponsored by AstraZeneca.

What drugs are being tested in NCT05143905?

Interventions in NCT05143905: AZD7503, Placebo.

What condition does NCT05143905 study?

NCT05143905 studies Safety, Tolerability, Pharmacokinetics, Healthy Participants.

Is NCT05143905 still recruiting?

NCT05143905 is currently completed. Last updated 19 February 2025.

Last reviewed 2025-02-19 · How we verify

NCT05143905

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7503 in Healthy Participants

Completed Phase 1 Last updated 19 February 2025

What this trial tests

Phase 1 trial testing AZD7503 in Safety in 56 participants. Completed in 9 November 2022.

Timeline

6 December 2021

Primary endpoint
9 November 2022

9 November 2022

Quick facts

Lead sponsor	AstraZeneca
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	double
Primary purpose	treatment
Enrollment	56
Start date	6 December 2021
Primary completion	9 November 2022
Estimated completion	9 November 2022
Sites	1 location across United States

Drugs / interventions tested

AZD7503 — full drug profile →
Placebo

Conditions studied

Safety — all drugs for Safety →
Tolerability — all drugs for Tolerability →
Pharmacokinetics — all drugs for Pharmacokinetics →
Healthy Participants — all drugs for Healthy Participants →

Sponsor

AstraZeneca — full company profile →

Who can join

Adults 18 to 65, any sex, with Safety or Tolerability. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will evaluate safety, tolerability and pharmacokinetics (PK) of AZD7503, following subcutaneous (SC) administration of single ascending doses of AZD7503 in healthy participants.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Oligonucleotide therapies for nonalcoholic steatohepatitis.
Li S, Xiong F, Zhang S, Liu J, et al · · 2024 · cited 19× · PMID 38665220 · DOI 10.1016/j.omtn.2024.102184
Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis.
Devasia AG, Ramasamy A, Leo CH. · · 2025 · cited 16× · PMID 40004240 · DOI 10.3390/ijms26041778
Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease.
Schwabe RF, Tacke F, Sugimoto A, Friedman SL. · · 2025 · cited 13× · PMID 40689145 · DOI 10.1016/j.jhepr.2025.101421
Alternative splicing: hallmark and therapeutic opportunity in metabolic liver disease.
Jiang M, Alqahtani SA, Seto WK, Yilmaz Y, et al · · 2025 · cited 2× · PMID 40438258 · DOI 10.1093/gastro/goaf044
Gene-based therapies for steatotic liver disease.
Iakovleva V, de Jong YP. · · 2025 · cited 2× · PMID 40254880 · DOI 10.1016/j.ymthe.2025.04.024
Genomic medicine in hepatology: mechanisms and liver treatment strategies.
Kozlov DS, Rodimova S, Filatov P, Mozherov A, et al · · 2025 · cited 1× · PMID 41023586 · DOI 10.1186/s10020-025-01358-4
Genetic Predisposition to MASLD: Potential for Therapeutic Management
· 2026

Verify or expand the search:

Other trials of AZD7503

Trials testing the same drug.

NCT05864391 — A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD7503 in Participants With Suspected NASH. · Phase 1 · terminated

Other recruiting trials for Safety

Currently open trials in the same condition.

NCT06818994 — Safety and Efficacy of Psilocybin-assisted Psychotherapy for Demoralization Syndrome in Patients Diagnosed With Advanced · Phase 1 · recruiting
NCT07286656 — A Study of GensSci098 in Subjects With Graves' Disease · Phase 1 · recruiting
NCT06760208 — A Study to Learn More About Prevenar 20 Once it is Out in the Korean Market · recruiting
NCT07157215 — An International Survey on the Use of NIV Outside the ICU · recruiting
NCT06976229 — Safety and Early Efficacy of iPSC-Derived Motor Neuron Progenitor Cells (XS228) in Subacute Spinal Cord Injury: A Phase · Phase 1 · recruiting

Other AstraZeneca trials

Trials by the same sponsor.

NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05143905 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
Last refreshed: 19 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05143905.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing